SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-363045
Filing Date
2021-12-21
Accepted
2021-12-21 07:48:01
Documents
12
Period of Report
2021-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d251066d8k.htm   iXBRL 8-K 27662
  Complete submission text file 0001193125-21-363045.txt   150828

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kpti-20211217.xsd EX-101.SCH 2886
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20211217_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20211217_pre.xml EX-101.PRE 11404
6 EXTRACTED XBRL INSTANCE DOCUMENT d251066d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 211506842
SIC: 2834 Pharmaceutical Preparations